Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpRegen in Geographic Atrophy Secondary to AMD
NCT05626114Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Mar 2023
- Primary completion
- Mar 2031
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of OpRegen in geographic atrophy (GA), sponsored by Genentech. Primary endpoints: Proportion of Participants With Subretinal Surgical Delivery of OpRegen to Target Regions at 3 months and Incidence and Severity of Procedure-related Adverse Events (AEs) at 3 months. Started Mar 2023; status: recruiting.
02
Drugs
OpRegen
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT05626114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626114.